Immunomodulatory and therapeutic properties of FK-565 in mice.
The heptanoyl tripeptide, FK-565 is a biological response modifier with potent therapeutic properties for the treatment of experimental and spontaneous metastases. Doses of FK-565 greater than 5 mg/kg are required for in vivo augmentation of natural killer cells, macrophages, and for therapeutic activity, presumably because FK-565 is a peptide small molecular mass which is rapidly degraded and excreted. Optimal therapeutic activity is observed at approximately 25-50 mg/kg FK-565, administered i.v. three times per week for 4 weeks. In addition to its therapeutic properties, which were consistently greater than the positive control at optimal doses, FK-565 had significant immunoaugmentary properties for natural killer cells, macrophages, and T cells both in vitro and in vivo, suggesting that its therapeutic activity is due to immune augmentation.
Talmadge
J E
JE
Department of Immunology, Smith Kline & French Laboratories, King of Prussia, PA 19406-0939.
Lenz
B
B
Schneider
M
M
Phillips
H
H
Long
C
C
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D007694:Killer Cells, Natural / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D008262:Macrophage Activation / Q000187:drug effects; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D009842:Oligopeptides; C039537:heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine